A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age12+

SponsorGuangdong Hengrui Pharmaceutical Co., Ltd

About this trial

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype

At least 12 years of age

A minimum weight of 40kg

A medical history of at least 1 year that meets the diagnosis of asthma;

Current treatment with medium- or high- doses of ICS for at least 6 months and using steadily at least 3 months

With other condition that could lead to elevated eosinophils

With Clinically significant pulmonary diseases

With existing immunodeficiency disease

With other clinically significant diseases that may affect lung function

400 Participants

are divided into 2 treatment groups

Guangdong Hengrui Pharmaceutical Co., Ltd

Lead sponsor